In summary, the combination of Inavolisib and CDK4/6 inhibitors provides a new treatment paradigm for PIK3CA-mutated breast cancer by synergistically blocking the PI3K signaling pathway and cell cycle progression. This evidence concerns the gene PIK3CA and breast cancer.